Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis

Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of... IntroductionPsoriasis is an immune‐mediated inflammatory disease that affects approximately 1–3% of the population worldwide. An increasing body of evidence supports that the inflammatory process in psoriasis may have systemic consequences with implications for the development of psoriatic comorbidities, including cardiovascular disease (CVD). Psoriasis was suggested to be an independent risk factor for atherosclerosis and CVD.Current concepts favour the idea that inflammation provides a pivotal link between psoriasis and atherosclerosis, which seems to be responsible for the association between the two diseases. Overall, many of the inflammatory products produced in psoriatic skin lesions appear to be released into the systemic circulation as a function of the severity and extent of skin lesions. During periods of active disease, skin‐derived inflammatory products could alter the properties of leucocytes while circulating through the inflamed cutaneous vasculature, or affect endothelial cells at distant sites.The S100 proteins constitute a family of small calcium‐binding proteins that are increasingly recognised as potential players in the pathogenesis of various inflammatory diseases. Several lines of evidence support a crucial role of S100 proteins in the pathogenesis of atherosclerosis, and several S100 molecules have been found to be upregulated in psoriasis, implicating their involvement in its pathogenesis.The antimicrobial S100A proteins http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical & Experimental Dermatology Wiley

Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis

Download PDF
6 pages

Loading next page...
1
 
/lp/wiley/serum-levels-of-psoriasin-s100a7-and-koebnerisin-s100a15-as-potential-ZfJYSRbNwG

References (26)

Publisher
Wiley
Copyright
Copyright © 2018 British Association of Dermatologists
ISSN
0307-6938
eISSN
1365-2230
DOI
10.1111/ced.13370
pmid
29333662
Publisher site
See Article on Publisher Site

Abstract

IntroductionPsoriasis is an immune‐mediated inflammatory disease that affects approximately 1–3% of the population worldwide. An increasing body of evidence supports that the inflammatory process in psoriasis may have systemic consequences with implications for the development of psoriatic comorbidities, including cardiovascular disease (CVD). Psoriasis was suggested to be an independent risk factor for atherosclerosis and CVD.Current concepts favour the idea that inflammation provides a pivotal link between psoriasis and atherosclerosis, which seems to be responsible for the association between the two diseases. Overall, many of the inflammatory products produced in psoriatic skin lesions appear to be released into the systemic circulation as a function of the severity and extent of skin lesions. During periods of active disease, skin‐derived inflammatory products could alter the properties of leucocytes while circulating through the inflamed cutaneous vasculature, or affect endothelial cells at distant sites.The S100 proteins constitute a family of small calcium‐binding proteins that are increasingly recognised as potential players in the pathogenesis of various inflammatory diseases. Several lines of evidence support a crucial role of S100 proteins in the pathogenesis of atherosclerosis, and several S100 molecules have been found to be upregulated in psoriasis, implicating their involvement in its pathogenesis.The antimicrobial S100A proteins

Journal

Clinical & Experimental Dermatology – Wiley

Published: Jan 1, 2018

There are no references for this article.